Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
26.09.24
/
50%
€49.00
Target price
26.09.25
€69.10
Performance (%)
-1.22%
Price
27.09.24
€48.40
Summary
This prediction is currently active. With a performance of -1.22%, the BUY prediction by Royal_Bank_of_Canada is trending in the wrong direction. This prediction currently runs until 26.09.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Ultragenyx Pharmaceutical Inc. | -1.22% |
iShares Core DAX® | 3.523% |
iShares Nasdaq 100 | 1.026% |
iShares Nikkei 225® | -0.063% |
iShares S&P 500 | 0.557% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€41.20
22.04.24
22.04.24
€72.35
22.04.25
22.04.25
19.90%
27.09.24
27.09.24